GSK's Tyverb approved for use with Herceptin
This article was originally published in Scrip
Executive Summary
The European Commission has granted a label expansion for GlaxoSmithKline's Tyverb (lapatinib). It can now be used in combination with trastuzumab (Herceptin) in adult patients with HER2-positive, hormone receptor-negative metastatic breast cancer that has progressed on prior trastuzumab therapy in combination with chemotherapy.